Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani

Archives of Pathology and Laboratory Medicine

Volumn 120, Issue 2, 1996, Pages 189-198

  Albrecht, Helmut ^a   Sobottka, Ingo ^a   Emminger, Christoph ^b   Jablonowski, Helmut ^c   Just, Gudrun ^d   Stoehr, Albrecht ^e   Kubin, Thomas ^f   Salzberger, Bernd ^g   Lutz, Thomas ^d   Van Lunzen, Jan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinikum Schwabing   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e St Georgs Hospital   (Germany)

^f City Hospital of Karlsruhe   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LEISHMANIA DONOVANI; MALE; OPPORTUNISTIC INFECTION; VISCERAL LEISHMANIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; FATAL OUTCOME; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PREVALENCE;

EID: 9044253318     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Badaro R, Jones TC, Lorenco R, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis. 1986;154:639-649.
2. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003-1011.
3. Ho M, Siongok TK, Lyerly WH, Smith DH. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg. 1964;58:377-390.
4. Condom MJ, Clotet B, Sirera C, Milla F, Foz M. Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989;111: 767-768.
5. Sirera G, Milla F, Condom MJ, Clotet B. Asymptomatic visceral leishmaniasis in a patient with acquired immunodeficiency syndrome. Med Clin (Barc). 1990;94:196.
6. Albrecht H, Stellbrink HJ, Gross G, Berg B, Helmchen U, Mensing H. Treatment of atypical leishmaniasis with interferon-gamma resulting in progression of Kaposi's sarcoma in an AIDS patient. Clin Invest. 1994;71:1041-1047.
7. Fenske S, Stellbrink HJ, Albrecht H, Greten. Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment. Klin Wochenschr. 1991;69:793-796.
8. Elsing C, Erckenbrecht JF, Strohmeyer G, Borchard F. HIV infection and kalaazar. Dtsch Med Wochenschr. 1989;114:1176.
9. Betz P, Elsing C, Purrmann J, Frenzel H. Leishmaniasis of the upper gastrointestinal tract in an HIV-positive patient. Pathologe. 1990;11:97-100.
10. Just G, Simader R, Helm EB, et al. Visceral leishmaniasis (kala-azar) in acquired immunodeficiency syndrome (AIDS). Dtsch Med Wochenschr. 1988;113:1920-1922.
11. Jablonowski H, Szelenyi H, Borchard F, Doehring-Schwerdtfeger E, Hengels KJ. Viszerale Leishmaniose mit gastrointestinalem Befall bei einer 30-jaehrigen HIV-infizierten Patientin. (Visceral leishmaniasis with gastrointestinal involvement in a 30-year-old HIV-infected patient). Z Gastroenterol. 1994;32:405-407.
12. Altes J, Salas A, Riera M, et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 1991;5:201-207.
13. Alvar J, Blazquez J, Najera R. Association of visceral leishmaniasis and human immunodeficiency virus infections. J Infect Dis. 1989;160:560-561.
14. Alvar J, Gutierrez-Solar B, Molina R. Prevalence of Leishmania infection among AIDS patients. Lancet. 1992;339:1427.
15. Alvar J, Jimenez M. Could infected drug-users be potential Leishmania infantum reservoirs? AIDS. 1994;8:854.
16. Berenguer J, Moreno S, Cercenado E, Bernaldo de Quiros JCL, Garcia de la Fuente A, Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med. 1989;111:129-132.
17. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal Amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994;87:75-81.
18. Del mar Sanz M, Rubio R, Casillas A, et al. Visceral leishmaniasis in HIV-infected patients. AIDS. 1991;10:1272-1274.
19. Medrano FJ, Hernandez-Quero J, Jimenez E, et al. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS. 1992;6:1499-1503.
20. Montalban C, Martinez Fernandez R, Calleja J, et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis. 1989;11:655-660.
21. Montalban C, Calleja JL, Erice A, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect. 1990;21:261-270.
22. Montalban C, Sevilla F, Moreno A, Nash R, Calma MI, Munoz RF. Visceral leishmaniasis as an opportunistic infection in the acquired immunodeficiency syndrome. J Infect. 1987;15:247-250.
23. Paez Pena M, Gomez Rodrigo J, Padilla B, Delgado Iribarren A, Guerra L, Jusdado J. Visceral leishmaniosis and HIV infection: is secondary prophylaxis needed? Int Conf AIDS. 1992;8:115. Abstract PuB 7401.
24. Gazapo E, Laguna F, Martinez P, Adrados M, Martinez ML, Diaz F. Visceral leishmaniasis secondary prophylaxis in HIV patients. int Conf AIDS. 1992;8:82. Abstract PuB 7200.
25. Peters BS, Fish D, Golden R, Evans DA, Bryceson AD, Pinching AJ. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med. 1990;77:1101-1111.
26. Piarroux R, Gambarelli F, Dumon H, et al. Comparison of PCR with direct bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol. 1994;32:746-749.
27. Rosenthal E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg. 1995;89:159-162.
28. Marsden PD. Selective primary health care: strategies of control of disease in the developing world. Rev Infect Dis. 1984;6:736-744.
29. Leishman WB. Handbuch der Tropenkrankheiten. 2nd ed. Leipzig, Germany: A. Barth; 1906.
30. de Rossill RA, de Duran RJ, Rossell O, Rodriguez AM. Is leishmaniasis ever cured? Trans R Soc Trop Med Hyg. 1992;86:251-253.
31. Pearson RD, Wheeler DA, Harrison LH, Kay HD. The immunobiology of leishmaniaisis. Rev Infect Dis. 1983;5:907-927.
32. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazzard for the host. Infect Immun. 1993;61:220-226.
33. Badaro R, Carvalho EM, Rocha H, Quieroz AC, Jones TO. Visceral leishmaniasis: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet. 1986;i:647-648.
34. Fernandez-Guerrero ML, Aguado JM, Buzon L, et al. Visceral leishmaniasis in immunocompromised host. Am J Med. 1987;83:1098-1102.
35. Ma DDF, Concannon AJ, Hayes J. Fatal leishmaniasis in renal-transplant recipient. Lancet. 1979;ii:311-312.
36. Senaldi G, Cadeo G, Carnevale G, Di Perri G, Carosi G. Visceral leishmaniasis as an opportunistic infection. Lancet. 1986;i:1094.
37. Bogdan C, Gessner A, Röllinghoff M. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology. 1993;189:356-396.
38. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular L. donovani by lymphokine-stimulated human mononuclear phagocytes: evidence that interferon-gamma is the activating lymphokine. J Clin Invest. 1983;72:1506-1510.
39. Murray HW, Squires KE, Miralles CD, et al. Acquired resistance and granuloma formation in experimental visceral leishmaniasis: differential T-cell and lymphokine roles in initial versus established immunity. J Immunol. 1992;148: 1858-1863.
40. Heinzel FP, Sadick MD, Holaday BJ, et al. Reciprocal expression of interferon-gamma or interleukin-4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T-cell subsets. J Exp Med. 1989;169:59-72.
41. Reiner SL, Wang ZE, Hatam F, et al. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science. 1993;259:1457-1460.
42. Badaro R, Johnson WD Jr. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis. 1993;167(suppl 1): 13-17.
43. van Lunzen J, Kern P, Schmitz J, et al. Short-term treatment of visceral leishmaniasis of the Old World with low dose interferon-gamma and pentavalent antimony. Infection. 1993;21:362-366.
44. Crawford GD, Wyler DJ, Dinarello CA. Parasite-monocyte interactions in human leishmaniasis: production of interleukin-1 in vitro. J Infect Dis. 1985;152: 315-322.
45. Reiner NE, Ng W, McMaster WR. Parasite-accessory cell interactions in murine leishmaniasis: II. L. donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. I Immunol. 1987;138:1926-1932.
46. Carvalho EM, Badaro R, Reed SG, et al. Absence of gamma-interferon and interleukin-2 production during active visceral leishmaniasis. J Clin Invest. 1985;76:2066-2069.
47. Carvalho EM, Teixeira RS, Johnson WD. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun. 1981;33:498-500.
48. Liew FY, Li Y, Yang DM, et al. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis. Immunology. 1991;74:304-309.
49. Reiner NE, Ng W, Wilson CB, et al. Modulation of in vitro monocyte cytokine responses to L. donovani: interferon-gamma prevents parasite-induced inhibition of interleukin-1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin-1. J Clin Invest. 1990;85:1914-1924.
50. Symmers WSC. Leishmaniasis acquired by contagion: a case of a marital infection in Britain. Lancet. 1960;i:127-132.
51. Gramiccia M, Gradoni L, Troiani M. HIV-leishmania co-infections in Italy: isoenzyme characterisation of Leishmania causing visceral leishmaniasis in HIV patients. Trans R Soc Trop Med Hyg. 1992;86:161-163.
52. + lymphocytopenia in the absence of HIV infection in a patient with visceral leishmaniasis. N Engl J Med. 1990;322:132.
53. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(RR-17):1-19.